## Granules India Limited (GRANULES) Stock Investment Report - December 20, 2024

**1. Company Overview:**

Granules India Limited (GRANULES) is a pharmaceutical company listed on the NSE (National Stock Exchange of India) on June 20, 2005.  It operates in the Pharmaceuticals industry, focusing on the manufacturing and supply of pharmaceutical products.  The company's positioning within the sector is as a significant player in the production of active pharmaceutical ingredients (APIs) and pharmaceutical formulations.


**2. Market Data Analysis:**

| Metric                     | Value          | Notes                                                              |
|-----------------------------|-----------------|----------------------------------------------------------------------|
| Current Price               | ₹591            |  Down ₹9.05 (-1.51%) from previous close.                             |
| Percentage Change (PChange) | -1.51%          | Negative daily performance.                                          |
| Pre-Open Activity          | ₹602.5 (Up 0.41%) | Positive pre-open activity, but closed lower than pre-open price. |
| Week High                   | ₹721 (30-Aug-2024) | Significant high in recent weeks.                                    |
| Week Low                    | ₹365.45 (21-Dec-2023) | Significant low in recent weeks, indicating volatility.              |
| VWAP                        | ₹601.03         | Volume Weighted Average Price slightly above current price.          |
| Sector PE                   | 29.87           | Industry average Price-to-Earnings ratio.                           |
| Symbol PE                   | 29.87           | GRANULES' Price-to-Earnings ratio, in line with the sector.         |
| Delivery Percentage         | 52.61%          | Relatively high delivery percentage suggests some institutional interest.|
| Market Depth                | Low              |  Order book data shows low market depth, indicating potential price swings. |


**3. Financial Performance:**

The following table summarizes Granules India's financial performance over the past five quarters (all figures in ₹ Crores):

| Quarter Ending      | Revenue     | Expenditure | Profit After Tax | Diluted EPS |
|----------------------|-------------|-------------|-----------------|-------------|
| 30-Sep-2024 (Un-Audited) | 57077.1     | 51469.7     | 4139.2          | 1.71        |
| 30-Jun-2024 (Un-Audited) | 85375.8     | 72789.9     | 9377.9          | 3.87        |
| 31-Mar-2024 (Audited)   | 94361.6     | 80710.5     | 9721.6          | 4.01        |
| 31-Dec-2023 (Un-Audited) | 98515.1     | 79353.9     | 14270.5         | 5.89        |
| 30-Sep-2023 (Un-Audited) | 101066.5    | 85465.2     | 11615.7         | 4.8         |

**Key Observations:**

* Revenue shows fluctuation across quarters.  There's a significant drop in Q2 FY25 (Sep 2024) compared to previous quarters.
* Profit after tax also shows significant variation, mirroring the revenue trend.
* Diluted EPS follows the same pattern as profit after tax.  Further analysis of the financial statements is needed to understand the reasons behind these fluctuations.


**4. Corporate Actions and Announcements:**

Recent corporate actions include dividend payments (most recently ₹1.50 per share with an ex-date of July 30, 2024).  Several announcements regarding loss of share certificates and changes in management have been made recently.  These announcements, while not directly impacting the stock price significantly in the short term, highlight potential governance and operational risks.


**5. Shareholding Patterns:**

| Quarter Ending | Promoter & Promoter Group | Public | Shares held by Employee Trusts | Total |
|-----------------|---------------------------|--------|-------------------------------|-------|
| 30-Sep-2023     | 41.96%                     | 58.04% | 0.00%                          | 100.00%|
| 31-Dec-2023     | 41.96%                     | 58.04% | 0.00%                          | 100.00%|
| 31-Mar-2024     | 41.96%                     | 58.04% | 0.00%                          | 100.00%|
| 30-Jun-2024     | 38.87%                     | 61.13% | 0.00%                          | 100.00%|
| 30-Sep-2024     | 38.87%                     | 61.13% | 0.00%                          | 100.00%|

**Key Observations:**

A notable decrease in promoter holding from approximately 42% to 39% between June 2024 and September 2024. This warrants further investigation into the reasons behind this reduction.


**6. Volatility and Risk Assessment:**

The stock exhibits high volatility, as evidenced by the significant difference between the week's high and low.  The CM Annual Volatility of 48.14% further confirms this.  The low market depth adds to the risk, as large trades could easily move the price.  The risk-reward profile is currently skewed towards risk due to the recent price decline and volatility.


**7. Advantages of Buying the Stock:**

* Established player in the pharmaceutical sector.
* Consistent dividend payouts (historical data).
* Potential for growth in the pharmaceutical industry.


**8. Disadvantages and Risks:**

* High volatility and low market depth.
* Recent decline in revenue and profit.
* Decrease in promoter holding.
* Several recent announcements regarding loss of share certificates and management changes raise concerns about corporate governance.


**9. Investment Horizon Recommendations:**

* **Short-term (less than 3 months): Don't Buy.** The recent price decline, high volatility, and low market depth make a short-term investment risky.  The negative price momentum and uncertainty surrounding the recent announcements further support this recommendation.

* **Medium-term (3 to 12 months): Hold (if you have stock).**  A medium-term outlook requires monitoring the company's financial performance and addressing the concerns raised by the decrease in promoter holding and the recent announcements.  If the company can demonstrate improved financial performance and address governance concerns, the outlook could improve.

* **Long-term (1 year and beyond): Hold (if you have stock).**  The long-term prospects depend on the company's ability to navigate the current challenges and maintain its position in the pharmaceutical sector.  Continued monitoring of financial performance and corporate governance is crucial.


**10. Stock and Analysis Scoring:**

**Stock Score (out of 10): 5.5**

* Financial Health: 4/10 (Fluctuating revenue and profit, needs further investigation)
* Market Performance: 3/10 (High volatility, recent price decline)
* Volatility and Risk: 2/10 (High volatility, low market depth)
* Corporate Actions & Governance: 6/10 (Consistent dividends, but recent governance concerns)
* Shareholding Patterns: 5/10 (Decrease in promoter holding)

**Analysis Score (out of 10): 9**

* Completeness and utilization of data: 10/10 (All provided data was used)
* Accuracy and clarity of analysis: 9/10 (Analysis is clear, but some assumptions were made due to limited data)
* Professional formatting: 10/10 (Report is well-formatted and easy to read)


**11. Professional Recommendation Summary:**

Granules India currently presents a mixed picture. While it operates in a growth sector and has a history of dividend payments, recent financial performance has been inconsistent, and concerns exist regarding promoter shareholding and corporate governance.  Therefore, a cautious approach is recommended.  For short-term investors, it's advisable to avoid the stock.  Medium-term and long-term investors should hold if they already own the stock, but closely monitor the company's performance and address the identified risks before making further investment decisions.  Further investigation into the reasons behind the revenue and profit fluctuations and the decrease in promoter holding is crucial before a more definitive recommendation can be made.
